Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Advanced Cancer
Interventions
DRUG

crizotinib

crizotinib 250 mg twice a day

DRUG

crizotinib

crizotinib 250 mg once a day

DRUG

crizotinib

crizotinib 250 mg twice a day

DRUG

crizotinib

crizotinib 250 mg once a day

DRUG

crizotinib

crizotinib 250 mg once a day

Trial Locations (20)

30308

Emory University Hospital Midtown Laboratory, Atlanta

30322

Emory University Hospital, Atlanta

Investigational Drug Service: The Emory Clinic Bldg A, Atlanta

The Emory Clinic, Atlanta

Winship Cancer Institute, Atlanta

43205

University Hospital East, Columbus

43210

Investigational Drug Services, Columbus

James Cancer Hospital, Columbus

The Ohio State University, Wexner Medical Center, Columbus

43221

Martha Morehouse Medical Plaza, Columbus

78229

Cancer Therapy & Research Center at UTHSCSA, San Antonio

Medical Arts and Research Center-MARC, San Antonio

80045

Anschutz Cancer Pavilion, Room 2224, c/o Melinda Friesleben, Pharm D, Aurora

University of Colorado Denver - Clinical Translational Research Center, Aurora

University of Colorado Denver, Anschutz Cancer Pavilion, Aurora

University of Colorado Denver, Anschutz Inpatient Pavillion, Aurora

90033

Keck Hospital of USC, Los Angeles

LAC&USC Medical Center, Los Angeles

USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01576406 - Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients | Biotech Hunter | Biotech Hunter